INSM Long Call Strategy
INSM (Insmed Incorporated), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.
INSM (Insmed Incorporated) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $25.57B, a beta of 0.89 versus the broader market, a 52-week range of 64.85-212.75, average daily share volume of 2.6M, a public-listing history dating back to 2000, approximately 1K full-time employees. These structural characteristics shape how INSM stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.89 places INSM roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.
What is a long call on INSM?
A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.
Current INSM snapshot
As of May 15, 2026, spot at $109.73, ATM IV 48.90%, IV rank 27.06%, expected move 14.02%. The long call on INSM below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this long call structure on INSM specifically: INSM IV at 48.90% is on the cheap side of its 1-year range, which favors premium-buying structures like a INSM long call, with a market-implied 1-standard-deviation move of approximately 14.02% (roughly $15.38 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated INSM expiries trade a higher absolute premium for lower per-day decay. Position sizing on INSM should anchor to the underlying notional of $109.73 per share and to the trader's directional view on INSM stock.
INSM long call setup
The INSM long call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With INSM near $109.73, the first option leg uses a $110.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed INSM chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 INSM shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $110.00 | $6.65 |
INSM long call risk and reward
- Net Premium / Debit
- -$665.00
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- -$665.00
- Breakeven(s)
- $116.65
- Risk / Reward Ratio
- Unbounded
Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.
INSM long call payoff curve
Modeled P&L at expiration across a range of underlying prices for the long call on INSM. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -100.0% | -$665.00 |
| $24.27 | -77.9% | -$665.00 |
| $48.53 | -55.8% | -$665.00 |
| $72.79 | -33.7% | -$665.00 |
| $97.05 | -11.6% | -$665.00 |
| $121.31 | +10.6% | +$466.40 |
| $145.57 | +32.7% | +$2,892.48 |
| $169.84 | +54.8% | +$5,318.56 |
| $194.10 | +76.9% | +$7,744.64 |
| $218.36 | +99.0% | +$10,170.72 |
When traders use long call on INSM
Long calls on INSM express a bullish thesis with defined risk; traders use them ahead of INSM catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
INSM thesis for this long call
The market-implied 1-standard-deviation range for INSM extends from approximately $94.35 on the downside to $125.11 on the upside. A INSM long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. Current INSM IV rank near 27.06% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on INSM at 48.90%. As a Healthcare name, INSM options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to INSM-specific events.
INSM long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. INSM positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move INSM alongside the broader basket even when INSM-specific fundamentals are unchanged. Long-premium structures like a long call on INSM are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current INSM chain quotes before placing a trade.
Frequently asked questions
- What is a long call on INSM?
- A long call on INSM is the long call strategy applied to INSM (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With INSM stock trading near $109.73, the strikes shown on this page are snapped to the nearest listed INSM chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are INSM long call max profit and max loss calculated?
- Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the INSM long call priced from the end-of-day chain at a 30-day expiry (ATM IV 48.90%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$665.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a INSM long call?
- The breakeven for the INSM long call priced on this page is roughly $116.65 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current INSM market-implied 1-standard-deviation expected move is approximately 14.02%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a long call on INSM?
- Long calls on INSM express a bullish thesis with defined risk; traders use them ahead of INSM catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
- How does current INSM implied volatility affect this long call?
- INSM ATM IV is at 48.90% with IV rank near 27.06%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.